Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

•Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry.•In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate.•Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia.•Baricitinb reduces SARS-CoV-2 viral burden detected by nasophary...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infection 2020-10, Vol.81 (4), p.647-679
Main Authors: Cantini, Fabrizio, Niccoli, Laura, Nannini, Carlotta, Matarrese, Daniela, Natale, Massimo Edoardo Di, Lotti, Pamela, Aquilini, Donatella, Landini, Giancarlo, Cimolato, Barbara, Pietro, Massimo Antonio Di, Trezzi, Michele, Stobbione, Paolo, Frausini, Gabriele, Navarra, Assunta, Nicastri, Emanuele, Sotgiu, Giovanni, Goletti, Delia
Format: Article
Language:English
Subjects:
Azetidines
Baricitinib
Betacoronavirus
Coronavirus Infections
COVID-19
Humans
JAK1/2
Letter to the Editor
Pandemics
Pilot Projects
Pneumonia
Pneumonia, Viral
Retrospective study
SARS-Co-V2
SARS-CoV-2
Sulfonamides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry.•In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate.•Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia.•Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab.•Baricitinib used for 2 weeks was not associated with serious adverse events. [Display omitted]
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2020.06.052